master. that s a type of judicially appointed person to do the review and they have to get the candidates in. so this person will review the documents that were seized. now, the doj is also at the same time appealing parts of this ruling saying that there s a national security risk to do this the way trump wants and that these are stolen documents that was partially signed off on by the magistrate to get the warrant so there s no reason donald trump would have great legal arguments to do anything about reviewing them let alone getting them back. so that would be a step. i say procedural because it s not the most important part of this case. we always try to keep it real with you. i m not going to play it up to sound urgent, although both sides care a lot about it. meanwhile, there s a new revelation from this case. more classified documents that the doj says trump stole might still be outstanding. that is to say missing. you see the headline there. the records could be tied t
Edition of booktv in primetime on cspan2. [inaudible conversations] hello, everyone. For those who were here this morning, welcome back. For those who are new to the session, welcome to the 2016 roosevelt reading festival. So glad to have you here today. I think you already know the format. I will talk for about a half hour, then about ten minutes of question and answer, and then hell go out and set up and be able to get signed copies of the book which are pretty wonderful. Were very excited about this ear year at the library. 75th every at 75th 75th anniversary at the end of the month, and this is something that franklin and Eleanor Roosevelt would be happy about. They want ted this site to be used as a center to bring people together to have a meaning philadelphia conversation. We have a membership table. We greatly appreciate it. The challenge we face here, with someone like david, is that he is highly accomplished and i could spend the next half hour talking bit his background but
### What you need to know
While mortality from acute cardiovascular disease (CVD) has been falling in most developed countries, more people are now living with established CVD, including coronary heart disease, peripheral arterial disease, and stroke or transient ischaemic attack. These individuals remain at high risk of subsequent cardiovascular events and mortality. In the UK, the cost of treating a myocardial infarction is £1310 higher in the first year for someone with established CVD than for a first event.1 Secondary prevention interventions, such as lowering of low density lipoprotein cholesterol (LDL-C), mitigate this risk and improve outcomes.2
Statins, ezetimibe, bempedoic acid, and injectable therapies are approved as lipid lowering therapies in the UK. However, use of these agents is variable,3 with about one fifth of people with CVD in England receiving no lipid lowering therapy.4 This is partly because of the absence of nationally agreed LDL-C targets for people with C